Abbott Laboratories (NYSE: ABT) is expected to report Q2 earnings on July 17. Here's what Wall Street wants to see:

The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Abbott Laboratories's revenues will wither -43.7% and EPS will shrink -64.2%.

The average estimate for revenue is $5.52 billion. On the bottom line, the average EPS estimate is $0.44.

Revenue details
Last quarter, Abbott Laboratories recorded revenue of $5.38 billion. GAAP reported sales were 1.8% higher than the prior-year quarter's $5.28 billion.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.

EPS details
Last quarter, non-GAAP EPS came in at $0.42. GAAP EPS of $0.34 for Q1 were 56% lower than the prior-year quarter's $0.78 per share.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.

Recent performance
For the preceding quarter, gross margin was 54.8%, 60 basis points worse than the prior-year quarter. Operating margin was 11.4%, 180 basis points better than the prior-year quarter. Net margin was 10.1%, much worse than the prior-year quarter.

Looking ahead

The full year's average estimate for revenue is $22.46 billion. The average EPS estimate is $2.01.

Investor sentiment
The stock has a five-star rating (out of five) at Motley Fool CAPS, with 2,518 members out of 2,610 rating the stock outperform, and 92 members rating it underperform. Among 648 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 633 give Abbott Laboratories a green thumbs-up, and 15 give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Abbott Laboratories is outperform, with an average price target of $35.37.

Is Abbott Laboratories the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.

Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor of Motley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.